Alan A. Kubey

Alan A. Kubey

Auto-generated profile, based on publicly available information

Alan A. Kubey

Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DCDagan Coppock
Dagan Coppock
MBMichael Baram
Michael Baram
ACAnna Marie Chang
Anna Marie Chang
PHPatricia Henwood
Patricia Henwood
AKAlan Kubey
Alan Kubey
BHBryan Hess
Bryan Hess
Introduction During the early months of the COVID-19 pandemic, mortality associated with the disease declined in the United States. The standard of care for pharmacological interventions evolved during this period as new and repurposed treatments were used alone and in combination. Though these medications have been studied individually, data are limited regarding the relative impact of different medication combinations. The objectives of this study were to evaluate the association of COVID-19-related mortality and observed medication combinations and to determine whether changes in medication-related practice patterns and measured patient characteristics, alone, explain the decline in mortality seen early in the COVID-19 pandemic. Methods A retrospective cohort study was conducted at a multi-hospital healthcare system exploring the association of mortality and combinations of remdesivir, corticosteroids, anticoagulants, tocilizumab, and hydroxychloroquine. Multivariable logistic regression was used to identify predictors of mortality for both the overall population and the population stratified by intensive care and non-intensive care unit admissions. A separate model was created to control for the change in unmeasured variables over time. Results For all patients, four treatment combinations were associated with lower mortality: Anticoagulation Only (OR 0.24, p < 0.0001), Anticoagulation and Remdesivir (OR 0.25, p = 0.0031), Anticoagulation and Corticosteroids (OR 0.53, p = 0.0263), and Anticoagulation, Corticosteroids and Remdesivir (OR 0.42, p = 0.026). For non-intensive care unit patients, the same combinations were significantly associated with lower mortality. For patients admitted to the intensive care unit, Anticoagulation Only was the sole treatment category associated with decreased mortality. When adjusted for demographics, clinical characteristics, and all treatment combinations there was an absolute decrease in the mortality rate by 2.5% between early and late periods of the study. However, when including an additional control for changes in unmeasured variables overtime, the absolute mortality rate decreased by 5.4%. Conclusions This study found that anticoagulation was the most significant treatment for the reduction of COVID-related mortality. Anticoagulation Only was the sole treatment category associated with a significant decrease in mortality for both intensive care and non-intensive care patients. Treatment combinations that additionally included corticosteroids and/or remdesivir were also associated with decreased mortality, though only in the non-intensive care stratum. Further, we found that factors other than measured changes in demographics, clinical characteristics or pharmacological interventions accounted for an additional decrease in the COVID-19-related mortality rate over time.

8 August 2023 in Journal of Hospital Medicine
Verified
Journal Article
Closed access
MBMaralyssa Bann
Maralyssa Bann
NMNicholas Meo
Nicholas Meo
JLJ. P. Lopez
J. P. Lopez
AOAmy Ou
Amy Ou
MRMolly Rosenthal
Molly Rosenthal
PHPaul Helgerson
Paul Helgerson

30 April 2022 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
PDF file
JRJoshua M. Riley
Joshua M. Riley
PMPatrick J. Moeller
Patrick J. Moeller
ACAlbert G. Crawford
Albert G. Crawford
JSJoseph W. Schaefer
Joseph W. Schaefer
DCDianna R. Cheney-Peters
Dianna R. Cheney-Peters
AKAlan A. Kubey
Alan A. Kubey

8 December 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
JSJoseph W. Schaefer
Joseph W. Schaefer
JRJoshua M Riley
Joshua M Riley
MLMichael Li
Michael Li
DCDianna R. Cheney‐Peters
Dianna R. Cheney‐Peters
CVChantel M. Venkataraman
Chantel M. Venkataraman
AKAlan A. Kubey
Alan A. Kubey
International Statistical Classification of Disease and Related Health Problems, 10th Revision codes (ICD‐10) are used to characterize cohort comorbidities. Recent literature does not demonstrate standardized extraction methods. Objective: Compare COVID‐19 cohort manual‐chart‐review and ICD‐10‐based comorbidity data; characterize the accuracy of different methods of extracting ICD‐10‐code‐based comorbidity, including the temporal accuracy with respect to critical time points such as day of admission. Design: Retrospective cross‐sectional study. Measurements: ICD‐10‐based‐data performance characteristics relative to manual‐chart‐review. Results: Discharge billing diagnoses had a sensitivity of 0.82 (95% confidence interval [CI]: 0.79–0.85; comorbidity range: 0.35–0.96). The past medical history table had a sensitivity of 0.72 (95% CI: 0.69–0.76; range: 0.44–0.87). The active problem list had a sensitivity of 0.67 (95% CI: 0.63–0.71; range: 0.47–0.71). On day of admission, the active problem list had a sensitivity of 0.58 (95% CI: 0.54–0.63; range: 0.30–0.68)and past medical history table had a sensitivity of 0.48 (95% CI: 0.43–0.53; range: 0.30–0.56). Conclusions and Relevance: ICD‐10‐based comorbidity data performance varies depending on comorbidity, data source, and time of retrieval; there are notable opportunities for improvement. Future researchers should clearly outline comorbidity data source and validate against manual‐chart‐review.

11 October 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
DCDianna R. Cheney‐Peters
Dianna R. Cheney‐Peters
CLCrystal Y. Lee
Crystal Y. Lee
SMShuji Mitsuhashi
Shuji Mitsuhashi
DZDina S. Zaret
Dina S. Zaret
JRJoshua M Riley
Joshua M Riley
AKAlan A. Kubey
Alan A. Kubey
Objective COVID-19 has disproportionately affected low-income communities and people of color. Previous studies demonstrated that race/ethnicity and socioeconomic status (SES) are not independently correlated with COVID-19 mortality. The purpose of our study is to determine the effect of race/ethnicity and SES on COVID-19 30-day mortality in a diverse, Philadelphian population. Methods This is a retrospective cohort study in a single center tertiary care hospital in Philadelphia, PA. The study includes adult patients hospitalized with polymerase-chain-reaction-confirmed COVID-19 between March 1st, 2020 and June 6th, 2020. The primary outcome was a composite of COVID-19 death or hospice discharge within 30 days of discharge. The secondary outcome was intensive care unit (ICU) admission. Results The study included 426 patients. 16.7% died, 3.3% were discharged to hospice, and 20.0% were admitted to the ICU. Using multivariable analysis, race/ethnicity was not associated with the primary nor secondary outcome. In Model 4, age greater than 75 (Odds Ratio [OR], 11.01; 95% confidence interval [CI], 1.96 to 61.97) and renal disease (OR 2.78; 95% CI, 1.31 to 5.90) were associated with higher odds of the composite primary outcome. “Very-low-income area” (OR 0.29; 95% CI, 0.12 to 0.71) and BMI 30-35 (OR 0.24; 95% CI, 0.08 to 0.69) were associated with lower odds of the primary outcome. Conclusions When controlling for demographics, SES, and comorbidities, race/ethnicity was not independently associated with the composite primary outcome. Very-low SES, as extrapolated from census-tract-level income data, were associated with lower odds of the composite primary outcome.

29 May 2025 in Journal of Hospital Medicine
Verified
Journal Article
Closed access
MKMichelle Knees
Michelle Knees
SFSarah J. Flynn
Sarah J. Flynn
EHEsther Y. Hsiang
Esther Y. Hsiang
AKAlan A. Kubey
Alan A. Kubey